Myositis Pipeline

DelveInsight’s, “Myositis Pipeline Insight, 2026” report provides comprehensive insights about 40+ companies and 45+ pipeline drugs in Myositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Myositis Understanding

Myositis Overview

Myositis, or idiopathic inflammatory myopathies (IIMs), represents a group of rare autoimmune disorders characterized by chronic inflammation and progressive weakness of skeletal muscles, with potential involvement of extramuscular organs such as the lungs, heart, and esophagus. Major subtypes include dermatomyositis (DM), polymyositis (PM), juvenile dermatomyositis (JDM), inclusion body myositis (IBM), immune-mediated necrotizing myopathy (IMNM), as well as overlap and antisynthetase syndromes, each with distinct clinical and immunological features.
Systemic features may include fever, weight loss, interstitial lung disease, Raynaud’s phenomenon, and dysphagia, with clinical presentation varying by subtype - dermatomyositis shows characteristic skin rashes, polymyositis presents with isolated muscle involvement, and inclusion body or necrotizing myopathy displays distinct progression patterns.

Pathophysiologically, myositis involves both innate and adaptive immune mechanisms: muscle injury releases DAMPs that activate Toll-like receptors, inducing pro-inflammatory cytokines, MHC class I upregulation, and inflammasome-driven inflammation. CD8⁺ T cells mediate fiber destruction in some subtypes, while autoantibody-driven complement activation causes vascular injury and necrosis in others. Non-immune factors such as mitochondrial dysfunction, oxidative stress, and impaired repair further exacerbate muscle damage, leading to chronic inflammation and progressive weakness.

Diagnosis of myositis requires a comprehensive, multimodal approach that integrates clinical evaluation, laboratory testing, imaging, electromyography (EMG), and muscle biopsy. The 2017 EULAR/ACR classification criteria help assess disease probability and differentiate IIMs from mimicking conditions. Clinical assessment focuses on symmetric proximal muscle weakness, characteristic skin findings, and systemic involvement, supported by elevated muscle enzymes and myositis-specific autoantibodies. EMG and MRI assist in confirming muscle inflammation, mapping affected regions, and guiding biopsy site selection, while muscle biopsy remains the gold standard for definitive subtype classification and individualized treatment planning.

Management begins with high-dose glucocorticoids, such as oral prednisolone or intravenous methylprednisolone for severe cases, to rapidly suppress inflammation, restore muscle strength, and normalize enzyme levels, followed by gradual tapering based on clinical response. Early introduction of steroid-sparing immunosuppressants, including methotrexate, azathioprine, or mycophenolate mofetil, helps maintain long-term disease control, reduce relapses, and minimize steroid-related adverse effects. Comprehensive care also includes physiotherapy and multidisciplinary support to preserve muscle function, improve mobility, and optimize overall quality of life.

"Myositis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myositis pipeline landscape is provided which includes the disease overview and Myositis treatment guidelines. The assessment part of the report embraces, in depth Myositis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myositis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Myositis pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Myositis Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Myositis R&D. The therapies under development are focused on novel approaches to treat/improve Myositis.

Myositis Emerging Drugs Analysis

This segment of the Myositis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myositis Emerging Drugs

PF-06823859: Pfizer

PF-06823859 is a humanized monoclonal antibody developed by Pfizer that targets interferon-beta, aiming to inhibit key inflammatory signaling pathways involved in idiopathic inflammatory myopathies. By reducing immune-mediated inflammation in muscle and skin tissues, it is designed to improve muscle strength and decrease disease activity in conditions such as dermatomyositis and polymyositis. This therapy represents a targeted approach to modulating cytokine-driven disease mechanisms. PF-06823859 is currently under evaluation in Phase III clinical trials for the treatment of myositis.

GLPG3667: Galapagos NV

GLPG3667 is an investigational, oral small-molecule TYK2 (tyrosine kinase 2) inhibitor developed by Galapagos, designed to selectively modulate key cytokine signaling pathways involved in autoimmune diseases. By inhibiting TYK2, it blocks downstream signaling of cytokines such as type I interferons, IL-12, and IL-23, thereby reducing immune-mediated inflammation in idiopathic inflammatory myopathies. In myositis, including dermatomyositis and polymyositis, this mechanism may help improve muscle strength, control skin manifestations, and decrease overall disease activity. The drug is currently in Phase II stage of its development for the treatment of myositis.

FT819: Fate Therapeutics

FT819 is an investigational, off-the-shelf allogeneic CAR T-cell therapy engineered to target CD19-positive B cells, developed using induced pluripotent stem cell (iPSC) technology. By selectively depleting pathogenic B cells, it aims to reduce autoantibody production and modulate aberrant immune responses involved in idiopathic inflammatory myopathies. In myositis, particularly autoantibody-driven subtypes, this approach may help decrease disease activity and improve muscle function. FT819 is currently in Phase I stage of its development.

Further product details are provided in the report……..

Myositis Drug Therapeutic Assessment

This segment of the report provides insights about the different Myositis drugs segregated based on following parameters that define the scope of the report, such as:

Major Myositis Players in Myositis

There are approx. 40+ key companies which are developing the therapies for Myositis. The companies which have their Myositis drug candidates in the most advanced stage, i.e. Phase III include, Pfizer.

Myositis Pipeline Clinical Trial Phases Phases

DelveInsight’s report covers around 45+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Myositis Drug Route of Administration

Myositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Myositis Product Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Myositis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myositis Clinical Trial Activities

The Myositis Pipeline report provides insights into different Myositis clinical trials within Phase III, II, I, preclinical and discovery stage. It also analyses Myositis therapeutic drugs key players involved in developing key drugs.

Myositis Pipeline Development Activities

The Myositis clinical analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myositis drugs.

Myositis Pipeline Report Insights

Myositis Pipeline Analysis
Myositis Therapeutic Assessment
Myositis Unmet Needs
Impact of Myositis Drugs

Myositis Pipeline Report Assessment

Myositis Pipeline Product Profiles
Myositis Therapeutic Assessment
Myositis Pipeline Assessment
Myositis Inactive drugs assessment
Myositis Market Unmet Needs

Key Questions Answered In The Myositis Pipeline Report:

Current Treatment Scenario and Emerging Therapies:
How many companies are developing Myositis drugs?
How many Myositis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myositis?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myositis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Myositis and their status?
What are the key designations that have been granted to the emerging drugs?